Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

New blog launched on Cyprotex website

Cyprotex today announces the launch of a new blog on its website www.cyprotex.com/blog
The purpose of the new blog is to keep the scientific community updated on:

• our research activities at Cyprotex

• important news articles from Cyprotex

• new regulatory updates which impact our activities

• interesting industry developments or articles.

Commenting on the launch of the blog, Dr Anthony D Baxter, Cyprotex’s Chief Executive Officer, said: ‘The blog will prove to be a valuable source of information for our customers and the research community. This initiative not only seeks to expand our website-driven customer base with a content-first strategy, but also aims to set Cyprotex apart as a thought leader and resource for the pharmaceutical, personal care, cosmetics and chemical industries.’

Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 900 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries.  The Company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close